RRIDs were included in the Molecular Cancer Therapeutics paper "Vimseltinib: A Precision CSF1R Therapy for Tenosyn…" (https://t.co/KX0JnYk37b). Thank you for making your #methodsmatter. #ReproducibleResearch
Myeloid cells can promote tumorigenesis making them a rational therapeutic target. This #FirstDisclosure paper the development of new CSF1R inhibitor vimseltinib and shows that it reduces tumor burden in patients with #TenosynovialGiantCellTumors. https://
#FirstDisclosure Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages https://t.co/7rq5UTMFai https://t.co/9zDS6TSfWC
#FirstDisclosure Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages https://t.co/pQcCYX7Ngb https://t.co/VMc4ocCGU4
RT @Deciphera: We’re pleased to share our newly published manuscript in @MCT_AACR on preclinical data of vimseltinib, our investigational s…
RT @Deciphera: We’re pleased to share our newly published manuscript in @MCT_AACR on preclinical data of vimseltinib, our investigational s…
RT @FilipJankuMD: Just came out in @MCT_AACR ! #Deciphera DCC-3014, a switch control inhibitor of CSF1R, looks promising in Tenosynovial Gi…
Just came out in @MCT_AACR ! #Deciphera DCC-3014, a switch control inhibitor of CSF1R, looks promising in Tenosynovial Giant Cell Tumor. Early clinically data were shown at #CTOS2020 and now the first mostly preclinical paper is out.
We’re pleased to share our newly published manuscript in @MCT_AACR on preclinical data of vimseltinib, our investigational switch-control kinase inhibitor of CSF1R. Learn more: https://t.co/hiseWyWtRj https://t.co/nfm83Pp400